Of note, studies assessing the effects of pharmacologic MR antagonism using spironolactone or eplerenone (27, 28) have shown that MR antagonism prevents liver steatosis in animal models of NASH, reinforcing the role of MR in modulating steatosis development. The gene discussed is NR3C2; the disease is fatty liver disease.